FDA Update: Importance of At Least Yearly, Lifelong Follow-Up with Use of Endologix AFX Endovascular Graft Systems

Today, the U.S. Food and Drug Administration (FDA) issued a safety communication to remind patients and health care providers of the importance of at least yearly, lifelong follow-up for all patients who have any type of Endologix AFX endovascular graft (AFX with Strata, AFX with Duraply, or AFX2) in order to monitor for Type III endoleaks.

Read More